CURX — Curanex Pharmaceuticals Inc Common Stock
NASDAQ · Healthcare · Biotechnology
$4.57
+$0.08 (+1.67%)
Curanex Pharmaceuticals Inc Common Stock (CURX) is a biotechnology company listed on NASDAQ. It is led by Jun Liu, based in 2 Jericho Plaza, Jericho, NY, United States, 11753. Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. Curanex Pharmaceuticals Inc was founded in 1996 and is headquartered in Jericho, New York.
Net income was -$954.1K. CURX currently screens at market cap $8.9M.
Use this CURX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CURX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CURX SEC filings page. Lician reads the product cache first so this HTML stays unique to Curanex Pharmaceuticals Inc Common Stock even when a live quote feed is slow.
About Curanex Pharmaceuticals Inc Common Stock
Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. Curanex Pharmaceuticals Inc was founded in 1996 and is headquartered in Jericho, New York.
CURX Key Statistics
Market Cap
$8.86M
Volume
323
Previous Close
$4.63
Day Range
$4.41 – $4.41
P/B Ratio
1.14
EPS
-$0.04
Revenue
$0.00
Net Income
-$954.06K
Gross Profit
$0.00
Free Cash Flow
$0.00
CURX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2025 | FY2025 | FY2024 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$954.06K | -$60.35K | -$137.58K | -$91.17K | -$44.20K |
| EPS (Diluted) | -$0.04 | $0.00 | $0.00 | -$0.04 | -$0.02 |
Total Assets
$14.48M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$5.80M
Operating Cash Flow
-$9.63M
Free Cash Flow
$0.00
Curanex Pharmaceuticals Inc Common Stock Company Information
- CEO, President & Chairman
- Jun Liu
- Headquarters
- 2 Jericho Plaza, Jericho, NY, United States, 11753
- Website
- www.curanexpharma.com
- Phone
- 718 673 6078
- IPO / Founded
- 2025-08-26
- Sector
- Healthcare
- Industry
- Biotechnology